Testing effectiveness (Phase 2)Ended earlyNCT01822275
What this trial is testing
Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
Who this might be right for
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
University of Maryland, Baltimore 24